An official website of the United States government
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Trial Status: active
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other
treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied
are either advanced (the cancer has spread to other parts of the body), or unresectable
(the cancer cannot be removed with surgery). The goals of this study are to learn:
- About the safety of sacituzumab tirumotecan alone or with other treatments and if
people tolerate it
- How many people have the cancer respond (get smaller or go away) to treatment
Inclusion Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has one of the following cancers:
- Unresectable or metastatic colorectal cancer and has received prior therapy for
the cancer
- Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received
prior therapy for the cancer
- Advanced and/or unresectable biliary tract cancer (BTC) and has received prior
therapy for the cancer
- Advanced and/or unresectable BTC and has not received prior therapy for the
cancer
- For participants who have received prior therapy for cancer: Has recovered from any
side effects due to previous cancer treatment
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- History of severe eye disease
- For participants who have received prior therapy for cancer: Received prior systemic
anticancer therapy including investigational agents within 4 weeks before starting
study intervention
- History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required
steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that
cannot be ruled out by standard diagnostic assessments at Screening
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06428409.
